Depot Medroxyprogesterone Acetate as Emergency Contraception
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Jan 4, 2018
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
The proposed study will enroll 36 healthy, non-pregnant, non-breastfeeding, reproductive age women with regular ovulatory cycles. Potential participants will undergo screening, which will include a history, physical exam, assessment of vital signs, and blood draw for assessment of ovulation via mid-luteal progesterone levels. If her progesterone level confirms ovulatory status (\> 3 ng/ml), she will be offered enrollment and assigned to one of three follicular phase groups based on her leading follicle size in the next cycle: 12-14 mm, 15-17 mm, and ≥18 mm. To determine follicle size, parti...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy women of reproductive age (18-39 years old) with BMI 18-30 kg/m2
- • Regular menses for the last 3 months
- • Cycle duration 24 to 35 days
- • Women using copper IUD, sterilization, or barrier methods as current or preferred birth control method, and women reporting exclusive sex with women
- • English- or Spanish-speaking
- Exclusion Criteria:
- • Any contraindications to progesterone contraception per teh CDC Medical Eligibility Criteria (Category 3 or 4)
- • On medications that can alter, or be altered by, progesterone contraceptive steroid hormone (e.g., aminoglutethimide or other anti-steroid medication)
- • Use of any hormonal contraceptive pill, patch, or vaginal ring in the month prior to recruitment
- • Use of depot-medroxyprogesterone acetate in teh 10 months prior to recruitment
- • Currently pregnant and/or breastfeeding
- • History of allergic reaction to depot medroxyprogesterone acetate (rash, urticaria, anaphylaxis)
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Robyn L Schickler, MD
Principal Investigator
University of Southern California
Brian Nguyen, MD, MSCP
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials